The glutamatergic N-methyl-D-aspartate (NMDA) receptors have been considered prime therapeutic targets for the development of useful neuroprotective strategies.
Recently a novel non-psychotomimetic class of NMDA receptor open-channel blockers with a diphenylpropylamine skeleton has been described. NPS 1506 [3-fluoro-g-(3-fluorophenyl)-N-methylbenzenepropamine] is representative of this class and currently used in human clinical trials for the treatment of acute ischemic stroke. 3, 4) Pharmacological studies on NPS 1506 have shown 5) : (1) that this molecule is a moderate-affinity uncompetitive NMDA receptor antagonist (IC 50 ϭ664 nM at displacing radioligand from [ 3 H]MK-801 labeled binding sites); and (2) that NPS 1506 is neuroprotective in a variety of animal models of stroke and head injury; (3) that, importantly, at doses greater than those required for neuroprotection, NPS 1506 did not elicit in rodents the characteristic side effect profile and had no PCP-like psychotomimetic effects at doses between 1-5 mg/kg i.p. in rats.
Such a pharmacological profile, different from the previous NMDA antagonists, led us to label NPS 1506 with carbon-11 and study the distribution and pharmacokinetics of the tracer in animals. Positron emission tomography (PET) is an imaging modality for in vivo assessment of drug distribution and interaction with biochemical target systems by the use of tracers labeled with positron emitters such as carbon-11 (T 1/2 ϭ20.4 min). 6) In this paper, we describe the synthesis of 11 C-labeled NPS 1506 and preliminary results on regional brain distribution studies by the tissue dissection method in mice and by PET in a rat, with special attention to the ability of specific binding in vivo.
MATERIALS AND METHODS

Nuclear magnetic resonance (
1 H-NMR) spectra were recorded on a JEOL GX-270 spectrometer 270 MHz with tetramethylsilane as an internal standard. All chemical shifts (d) are reported in parts per million (ppm) downfield from the standard. Mass spectra were obtained on a JMS DX-610 spectrometer. Infrared (IR) spectra were recorded with a JASCO IR Report-100 spectrometer. Column chromatography was done on Merck Kieselgel 60 (70-230 mesh), and analytical thin layer chromatography (TLC) was carried out on Silica gel 60 F 254 plates (Merck). In the synthetic procedures, organic extracts were routinely dried over anhydrous Na 2 SO 4 and evaporated with a rotatory evaporator under reduced pressure. Radioactivity was quantified with a IGC-3R Curiemeter (Aloka). High-pressure liquid chromatography (HPLC) was done using a Waters HPLC system for nonradioactive runs or a JASCO HPLC system for radioactive runs. Effluent radioactivity from the HPLC was determined using a NaI (Tl) scintillation detector system. Carbon-11 was generated by the 14 N(p, a) 11 C nuclear reaction using a CYPRIS HM-18 cyclotron (Sumitomo Heavy Industries, Ltd.). Preparation of [ 11 C]CH 3 I and subsequent 11 C-methylation were carried out automatically by using a synthetic apparatus for 11 C-labeled compounds developed by Suzuki et al. 7) 3-Nitropropionic acid was purchased from Sigma Co. and all reagents were used as received unless otherwise stated. The animal experiments were carried out according to the recommendations of the committee for the care and use of laboratory animals, National Institute of Radiological Sciences.
3-Fluoro-g g-(3-fluorophenyl)-N-methylbenzenepropamine (NPS 1506) To a stirred solution of the hydrochloride salt of 3-fluoro-g-(3-fluorophenyl)benzenepropamine (1) 8) (100 mg, 0.35 mmol) in a mixture of water and methanol (4 : 1, 2.5 ml) was added cyclopentadiene (130 ml, mmol). After 66 h, the reaction mixture was neutralized with a 5% sodium bicarbonate solution and extracted with methylene chloride (20 mlϫ3). The combined extracts were washed with a saturated NaCl aqueous solution (30 ml), dried and evaporated to dryness. The crude product was chromatographed on a silica gel with CHCl 3 : MeOH : NH 4 OHϭ 49 : 1 : 0.1 to provide 2-azanorbornene adduct (2) To a solution of the 2-azanorbornene (2) (35 mg, 0.108 mmol) in CHCl 3 (1 ml) was added trifluoroacetic acid (1 ml) and triethylsilane (165 ml, 1.03 mmol). The resulting mixture was stirred at room temperature for 72 h. The solvent was removed under reduced pressure. The crude product was dissolved in chloroform (0.5 ml), treated with 10% hydrochloric acid (5.0 ml), and washed with a mixture of hexane and ether (1 : 1). The aqueous layer was neutralized with a 5% sodium bicarbonate solution and then the product was extracted with methylene chloride. The combined extracts were washed with a saturated NaCl aqueous solution (20 ml), dried and evaporated to dryness. 
3-Fluoro-g g -(3-fluorophenyl)-N-[
11 C]methylbenzenepropamine ([ 11 C]NPS 1506) The hydrochloride salt of (1) was further purified by HPLC (column; nacalai tesque COSMOSIL 5C-18-MS, 10ϫ250 mm, mobile phase; CH 3 CN: 0.2% TFA in H 2 Oϭ35 : 65, flow rate; 4.0 ml/min) and the trifluoroacetic acid salt obtained (10 mg, 0.027 mmol) was neutralized with a 5% sodium bicarbonate solution (5 ml) and extracted with ether (5 mlϫ4). The combined extracts were washed with a saturated NaCl aqueous solution (20 ml), dried and evaporated to dryness to give the free base of (1) (7 mg, 100%). Preparation of [ 11 C]CH 3 I and subsequent 11 Cmethylation of (1) to [ 11 C]NPS1506 were achieved automatically using specially designed equipment.
7) The [ 11 C]CH 3 I prepared was trapped in anhydrous DMF (250 ml) containing the free base of (1) (1.0 mg) and NaH (4.5 ml, 1 M in DMF) at Ϫ15-Ϫ20°C. The reaction vessel was heated at 30°C and kept there for 3 min. After addition of an HPLC mobile phase (500 ml), the radioactive mixture was transferred onto an HPLC (column; nacalai tesque COSMOSIL 5C-18-MS, 10ϫ250 mm; mobile phase; CH 3 CN : 0.2% TFA in H 2 Oϭ 35 : 65, flow rate; 4.0 ml/min). A radioactive fraction having a retention time of 10 min was collected in a flask. After evaporation of the solvents from the flask under reduced pressure, the pure 40-42 g ). These mice (nϭ3 per time point) were killed at 1, 20, and 60 min by decapitation, the whole brains were rapidly removed and dissected into the cerebral cortex, striatum, hippocampus, and cerebellum. The samples were weighed and their radioactivities were measured with a Packard g-counter and corrected for decay. A sample of blood was also taken. The results were expressed as the percent of administered dose per gram of tissue (% dose/g). In separate experiments, the effect of the carrier dose on the brain uptake was investigated. Unlabeled NPS 1506 (3 mg/kg) was co-injected with [ 11 C]NPS 1506 into the mice, which were sacrificed at 20 min after injection. The brain was removed, dissected and regional radioactivity was determined as described above. The control mice were treated with a saline solution under identical conditions.
PET of [ 11 C]NPS 1506 in a Rat
One conscious rat (male Sprague-Dawley, 10 weeks old) was used for control scan and subsequent drug-pretreatment scan. The rat was fixed with a specifically designed head-hold device, 9) and PET scans were performed with a high-resolution SHR-7700 PET camera (Hamamatsu Photonics Shizuoka, Japan) which provides with 31 transaxial slices 3.6 mm (center-to-center) apart and a 14.8 cm field of view. After transmission scan for attenuation correction, dynamic emission scans were performed for 60 min (30 sϫ6 scans, 1 minϫ7 scans, 2 minϫ10 scans, 5 minϫ6 scans) following the [ 11 C]NPS 1506 injection (30 MBq and 54 MBq for control and pretreatment experiment, respectively) via the tail vein. The scan images were reconstructed with a Hanning filter of 4 mm, and circular regions of interest (ROIs) with a 5 mm diameter were placed over the striatum and hippocampus using image analysis software (in-house software PET Analyzer). The ROI values were expressed in kBq/ml, normalized to the injected radioactivity of 37 MBq, and plotted against time (Fig. 2) . In the pretreatment experiment, 3-nitropropionic acid (20 mg/kg, 11.6 mg/0.8 ml saline) was injected intraperitoneally 3 h prior to the [ 11 C]NPS 1506 injection.
RESULTS AND DISCUSSION
NPS 1506 presents in its chemical structure one N-methyl group, which was considered to the most accessible site for labeling with carbon-11 using [
11 C]methyl iodide. The precursor for 11 C-labeling, 3-fluoro-g-(3-fluorophenyl)benzenepropamine (1) was prepared according to the published method. 8) NPS 1506 as the reference compound was prepared by the two-step N-methylation via a retro aza DielsAlder reaction (Chart 1).
10) The immonium ion generated in situ from the hydrochloride salt of (1) and aqueous formaldehyde in water underwent a facile cyclocondenzation with cyclopentadiene to give the 2-azanorbornene adduct (2) in 91% yield. Subsequent treatment of (2) The brain biodistribution of [ 11 C]NPS 1506 after intravenous injection was investigated using mice (Table 1) . Blood radioactivity was very low at 1 min (ca. 1% dose/g) and fell to Ͻ0.5% dose/g at 20 min after injection, indicating a rapid distribution of [ 11 C]NPS 1506 into the tissues. Radioactivity uptake in the brain was high and increased slightly with time, indicative of good blood-brain penetration. The regional brain distribution was fairly uniform and did not clearly reflect the expected distribution which is based on the known localization of NMDA receptors in the rodent brain. 11, 12) We evaluated the effect of co-injection of unlabeled NPS 1506 (3 mg/kg per mouse) along with [ 11 C]NPS 1506 20 min after the tracer injection. As can be seen from Fig. 1 , treatment with unlabeled NPS 1506 did not cause any change of the uptake in the mouse brain compared to the control group, suggesting that the brain uptake observed was unlikely to be mediated by a saturable, specific mechanism.
In vivo distribution was further assessed in the rat brain. Figure 2 shows the time-activity curves (TACs) in the hippocampus and striatum containing high densities of NMDA receptor for 60 min PET scanning after intravenous injection of [ 11 C]NPS 1506. Regional radioactivity in the hippocampus and striatum gradually increased with time, having a plateau from 30 min onwards, again reflecting good penetration of the tracer across the BBB. Recent studies have shown that the channel open probability of the NMDA receptors is not very high at the normal brain activity. 13) It is known that 3-nitropropionic acid (3-NP) causes NMDA receptor activation in the striatum and cortex when administrated acutely to rats, as demonstrated by an increase in [ 3 H]MK-801 binding. 14) We examined the effect of prior treatment with 3-NP on the brain uptake of [ 11 C]NPS 1506. As can be seen from Fig. 2 , pretreatment with 3-NP (20 mg/kg) given intraperitoneally 3 h prior to tracer injection did not produce any change in the regional uptake in the hippocampus nor the striatum.
In summary, the labeling of NPS 1506 with carbon-11 in the N-methyl position was accomplished with high specific activity and high radiochemical purity. [ 11 C]NPS 1506 administered in tracer doses readily crosses the BBB consistent with its partition coefficient (log Pϭ3.81). 15) It has been reported that a number of NMDA receptor antagonists acting at the glycine site cross the BBB very poorly, despite their lack of dose-limiting side effects.
16) The good access of NPS 1506 to brain tissue gives it an advantage as an effective therapeutic agent over other antagonists. We could not prove that the accumulation of [ 11 C]NPS 1506 in rat and mouse brains was due to the specific binding to NMDA receptor binding sites. This could possibly result from both low in vitro affinity for NMDA receptors and large non-specific bound fractions, which might have masked the interaction with specific binding sites. In the present work, no metabolite studies were undertaken, and therefore whether the unspecific pattern of brain distribution of [ 11 C]NPS 1506 was due to radiolabeled metabolites that might have been formed in brain or penetrate the BBB remains uncertain. The observed brain retention of radioactivity may be related mainly to the affinity of 
